James W. Murrough, MD, PhD

JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
Rebecca S. Hock, Anna Feeney, Nadia Iovieno, et al
JCP
Meta-Analysis

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
Nadia Iovieno, George I. Papakostas, Anna Feeney, et al
JCP
Original Research

April 27, 2021

The pandemic has clearly placed a tremendous strain on health care workers, but how has it affected their ability to function in their daily lives and the likelihood of...
Lorig K. Kachadourian, Adriana Feder, James W. Murrough, et al
JCP
Meta-Analysis

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
George I. Papakostas, Naji C. Salloum, Rebecca S. Hock, et al
JCP
Educational Activity

July 30, 2019

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019...
Leslie Citrome, Bradley N. Gaynes, Joseph F. Goldberg, et al
JCP
Original Research

September 2, 2014

Le-Ben Wan, Cara F. Levitch, Andrew M. Perez, et al
JCP
Letter to the Editor

March 15, 2011

James W. Murrough, Andrew M. Perez, Sanjay J. Mathew, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe